<DOC>
	<DOCNO>NCT00593619</DOCNO>
	<brief_summary>The purpose trial compare safety profile use equal dos intravenous iron dextran versus iron sucrose . The researcher hypothesize significantly patient receive intravenous iron dextran ( use current intermediate molecular weight product ) severe adverse outcome patient receive iron sucrose adult non-hemodialysis outpatient population . Secondly , since severe reaction may require additional nursing time physician intervention may negate cost advantage iron dextran , researcher hypothesize iron sucrose cost-effective iron dextran .</brief_summary>
	<brief_title>Trial Comparing Safety Two Different Intravenous Iron Formulations</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Iron-Dextran Complex</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>Age 18 100 To receive intravenous iron Age &lt; 18 Hemodialysis Previous exposure intravenous iron Unable provide write consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Intravenous Iron</keyword>
	<keyword>Safety</keyword>
	<keyword>Perioperative</keyword>
	<keyword>Iron deficiency</keyword>
	<keyword>Non hemodialysis population</keyword>
	<keyword>Perioperative blood conservation</keyword>
</DOC>